BLAC vs. CNDA, RACY, AXAC, IVCB, MEAC, KVAC, GHIX, SEDA, MCAA, and BRKH
Should you be buying Bellevue Life Sciences Acquisition stock or one of its competitors? The main competitors of Bellevue Life Sciences Acquisition include Concord Acquisition Corp II (CNDA), Relativity Acquisition (RACY), AXIOS Sustainable Growth Acquisition (AXAC), Investcorp Europe Acquisition Corp I (IVCB), SEP Acquisition (MEAC), Keen Vision Acquisition (KVAC), Gores Holdings IX (GHIX), SDCL EDGE Acquisition (SEDA), Mountain & Co. I Acquisition Corp. (MCAA), and Burtech Acquisition (BRKH). These companies are all part of the "holding & other investment offices" industry.
Bellevue Life Sciences Acquisition (NASDAQ:BLAC) and Concord Acquisition Corp II (NYSE:CNDA) are both small-cap unclassified companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.
Bellevue Life Sciences Acquisition and Concord Acquisition Corp II both received 0 outperform votes by MarketBeat users.
Bellevue Life Sciences Acquisition has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500. Comparatively, Concord Acquisition Corp II has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500.
55.3% of Bellevue Life Sciences Acquisition shares are held by institutional investors. 25.3% of Bellevue Life Sciences Acquisition shares are held by company insiders. Comparatively, 0.2% of Concord Acquisition Corp II shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Bellevue Life Sciences Acquisition had 2 more articles in the media than Concord Acquisition Corp II. MarketBeat recorded 3 mentions for Bellevue Life Sciences Acquisition and 1 mentions for Concord Acquisition Corp II. Bellevue Life Sciences Acquisition's average media sentiment score of 1.56 beat Concord Acquisition Corp II's score of 1.00 indicating that Bellevue Life Sciences Acquisition is being referred to more favorably in the media.
Bellevue Life Sciences Acquisition's return on equity of 0.00% beat Concord Acquisition Corp II's return on equity.
Summary
Bellevue Life Sciences Acquisition beats Concord Acquisition Corp II on 5 of the 7 factors compared between the two stocks.
Get Bellevue Life Sciences Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bellevue Life Sciences Acquisition Competitors List
Related Companies and Tools
